Invimestrocel

英韦迈托赛

Report date: 2022/08/10 14:29:54

Base Information

Drug NameInvimestrocel
Drug Alias NameAMI MultiStemMultiStemPF-05285401HLCM 051
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Multipotent adult progenitor cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionCell replacementsImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsIschemic StrokeWounds and InjuriesNon-ST Elevated Myocardial Infarction +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAthersys Inc
China Registration ClassN/A

Develop Information

Active CompaniesHealios IncHealios Kk
Inactive CompaniesPfizer Inc
Active IndicationsWounds and InjuriesStrokeRespiratory Distress Syndrome, Adult
Inactive IndicationsIschemic StrokeNon-ST Elevated Myocardial InfarctionMyocardial Infarction +[5] 

Other Information

ATC CodeN/A
Related LinksN/A